2026 Global Biopharmaceutical M&A and VC Insights

A&M is pleased to present our 2025/2026 annual report on the state of the global biopharmaceutical sector. This comprehensive analysis explores the rebound in M&A activity, shifts in venture capital strategy, and the innovative approaches shaping today’s dealmaking environment.Read More

What's Trending

The U.S. wants Venezuelan oil. Does that undercut Canada’s leverage in trade talks?

Eurasia Group says no country more at risk than Canada in relations with the U.S.

‘Didn’t like us Canadians’: Snowbirds say tensions between Canada, U.S. led to changes in travel itinerary

Law Firm Faces Sanctions for Failing to Vet Ugandan Claims in $6B 3M Case

DNC warns Alabama secretary of state over potential federal voting law violations

Texas opens higher ed oversight office; public can report DEI, SB 37 violations

‘I don’t need international law’: Trump’s Wild West doctrine freezes European brains

Hamburg trial tests German law after US child’s suicide linked to murder charge

2026 Global Biopharmaceutical M&A and VC Insights

The U.S. wants Venezuelan oil. Does that undercut Canada’s leverage in trade talks?

Eurasia Group says no country more at risk than Canada in relations with the U.S.

‘Didn’t like us Canadians’: Snowbirds say tensions between Canada, U.S. led to changes in travel itinerary

‘51st state’ fear back in Canada after Trump’s Venezuela raid, Greenland threat: ‘Real risk of military coercion’

Leave A Reply Cancel Reply

What's Trending

2026 Global Biopharmaceutical M&A and VC Insights

Related Posts

Leave A Reply Cancel Reply

Subscribe to MGSN